Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Tizona Therapeutics, Inc
Second Life Therapeutics
Numab Therapeutics AG
Novartis
Cantargia AB
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)